51�Թ�

This is in part because it is not a controlled substance, unlike the other two medications, and in part because the drug’s maker, Alkermes, has heavily promoted it to those markets by claiming it is as safe as the other medications and easier to administer since it doesn’t have to be taken daily.

Alkermes engaged in intense political lobbying, emphasizing the dangers of the other drugs to Congress.

Alkermes had previously refreshed the board with new directors several times in recent years and has had success in developing and bringing new drugs to market.

Sarissa, which owns 8.5% of Alkermes, has long criticized the company's stock price and how the biotechnology company is run, and nominated three candidates, including its co-founder, Alex Denner, as director candidates to the 11-member board.

Alkermes licensed bipolar disorder treatment Lybalvi and the multiple sclerosis drug Vumerity to Biogen for commercialization, and some analysts worried it would be problematic for Denner to potentially sit on both companies' boards.